Immunopathogenesis versus Protection in Dengue Virus Infections

Current Tropical Medicine Reports

Volumn 1, Issue 1, 2014, Pages 13-20

  Rothman, Alan L ^a   Medin, Carey L ^a   Friberg, Heather ^b   Currier, Jeffrey R ^b  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Dengue; Dengue virus (DENV); DENV vaccine; Immunopathogenesis; Innate immunity; T lymphocyte; Vaccine; Viral disease; Viral tropical medicine

Indexed keywords

CD4 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; CYTOKINE; DNA VACCINE; GAMMA INTERFERON; INACTIVATED VACCINE; INTERLEUKIN 10; INTERLEUKIN 2; LIVE VACCINE; RECOMBINANT PROTEIN; RNA; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VIRUS PROTEIN; VIRUS VACCINE;

ADAPTIVE IMMUNITY; AUTOLYSOSOME; BLOOD VESSEL PERMEABILITY; CD4+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; DENGUE; DENGUE VIRUS; DISEASE SEVERITY; FLOW CYTOMETRY; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INFLAMMATION; INNATE IMMUNITY; LEUKOCYTE COUNT; MONOCYTE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SERODIAGNOSIS; T LYMPHOCYTE ACTIVATION; VACCINATION; VIRUS CELL INTERACTION; VIRUS LIKE AGENT; VIRUS REPLICATION;

EID: 84921022790     PISSN: None     EISSN: 21963045     Source Type: Journal    
DOI: 10.1007/s40475-013-0009-0     Document Type: Review

References (72)

1. Sabin AB. Research on dengue during World War II. Am J Trop Med Hyg. 1952;1(1):30–50.
2. Halstead SB, Nimmannitya S, Cohen SN. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med. 1970;42(5):311–28. PMCID: 2591704.
3. Burke DS, Nisalak A, Johnson DE, Scott RM. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg. 1988;38(1):172–80.
4. Thein S, Aung MM, Shwe TN, Aye M, Zaw A, Aye K, et al. Risk factors in dengue shock syndrome. Am J Trop Med Hyg. 1997;56(5):566–72.
5. Endy TP, Yoon IK, Mammen MP. Prospective cohort studies of dengue viral transmission and severity of disease. Curr Top Microbiol Immunol. 2010;338:1–13.
6. Halstead SB. Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion. Yale J Biol Med. 1970;42(5):350–62. PMCID: 2591710.
7. Simmons CP, Farrar JJ, Nguyen V, Wills B. Dengue. N Engl J Med. 2012;366(15):1423–32.
8. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis. 2000;181(1):2–9.
9. Libraty DH, Endy TP, Houng HS, Green S, Kalayanarooj S, Suntayakorn S, et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis. 2002;185(9):1213–21.
10. Srikiatkhachorn A, Wichit S, Gibbons RV, Green S, Libraty DH, Endy TP, Ennis FA, Kalayanarooj S, Rothman AL. Dengue viral RNA levels in peripheral blood mononuclear cells are associated with disease severity and preexisting dengue immune status. PLoS ONE. 2012;7(12):e51335. PMCID: 3526575. This study examined the distribution of DENV RNA among PBMC subsets during acute infection. Cell-associated DENV RNA levels were highest in B lymphocytes and monocyte fractions and were significantly higher in secondary DENV infections.
11. Yoon IK, Rothman AL, Tannitisupawong D, Srikiatkhachorn A, Jarman RG, Aldstadt J, Nisalak A, Mammen MP, Jr., Thammapalo S, Green S, Libraty DH, Gibbons RV, Getis A, Endy T, Jones JW, Koenraadt CJ, Morrison AC, Fansiri T, Pimgate C, Scott TW. Underrecognized mildly symptomatic viremic dengue virus infections in rural Thai schools and villages. J Infect Dis. 2012;206(3):389–98. PMCID: 3490697. This study enrolled individuals living near hospitalized dengue patients and detected subjects who were viremic but had minimal or no symptoms and maintained their normal daily activities. Such individuals in the community have the potential to contribute to DENV transmission.
12. Srikiatkhachorn A, Green S. Markers of dengue disease severity. Curr Top Microbiol Immunol. 2010;338:67–82.
13. Popper SJ, Gordon A, Liu M, Balmaseda A, Harris E, Relman DA. Temporal dynamics of the transcriptional response to dengue virus infection in Nicaraguan children. PLoS Negl Trop Dis. 2012;6(12):e1966. PMCID: 3527342.
14. Simmons CP, Popper S, Dolocek C, Chau TN, Griffiths M, Dung NT, et al. Patterns of host genome–wide gene transcript abundance in the peripheral blood of patients with acute dengue hemorrhagic fever. J Infect Dis. 2007;195(8):1097–107.
15. Green S, Pichyangkul S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Nisalak A, et al. Early CD69 expression on peripheral blood lymphocytes from children with dengue hemorrhagic fever. J Infect Dis. 1999;180:1429–35.
16. Welsch S, Miller S, Romero-Brey I, Merz A, Bleck CK, Walther P, et al. Composition and three-dimensional architecture of the dengue virus replication and assembly sites. Cell Host Microbe. 2009;5(4):365–75.
17. Miller S, Krijnse-Locker J. Modification of intracellular membrane structures for virus replication. Nat Rev Microbiol. 2008;6(5):363–74.
18. Heaton NS, Perera R, Berger KL, Khadka S, Lacount DJ, Kuhn RJ, et al. Dengue virus nonstructural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesis. Proc Natl Acad Sci U S A. 2010;107(40):17345–50. PMCID: 2951450.
19. Lee YR, Lei HY, Liu MT, Wang JR, Chen SH, Jiang-Shieh YF, et al. Autophagic machinery activated by dengue virus enhances virus replication. Virology. 2008;374(2):240–8.
20. Panyasrivanit M, Khakpoor A, Wikan N, Smith DR. Co-localization of constituents of the dengue virus translation and replication machinery with amphisomes. J Gen Virol. 2009;90(Pt 2):448–56.
21. Khakpoor A, Panyasrivanit M, Wikan N, Smith DR. A role for autophagolysosomes in dengue virus 3 production in HepG2 cells. J Gen Virol. 2009;90(Pt 5):1093–103.
22. McLean JE, Wudzinska A, Datan E, Quaglino D, Zakeri Z. Flavivirus NS4A-induced autophagy protects cells against death and enhances virus replication. J Biol Chem. 2011;286(25):22147–59. PMCID: 3121359. This report showed that the DENV NS4A protein induced PI3K-dependent autophagy and protected cells against death during infection.
23. Chang TH, Liao CL, Lin YL. Flavivirus induces interferon-beta gene expression through a pathway involving RIG-I-dependent IRF-3 and PI3K-dependent NF-kappaB activation. Microbes Infect. 2006;8(1):157–71.
24. Loo YM, Fornek J, Crochet N, Bajwa G, Perwitasari O, Martinez-Sobrido L, et al. Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J Virol. 2008;82(1):335–45. PMCID: 2224404.
25. Zhong B, Yang Y, Li S, Wang YY, Li Y, Diao F, et al. The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. Immunity. 2008;29(4):538–50.
26. Lee HK, Lund JM, Ramanathan B, Mizushima N, Iwasaki A. Autophagy-dependent viral recognition by plasmacytoid dendritic cells. Science. 2007;315(5817):1398–401.
27. Mackenzie J. Wrapping things up about virus RNA replication. Traffic. 2005;6(11):967–77.
28. Kou Z, Quinn M, Chen H, Rodrigo WW, Rose RC, Schlesinger JJ, et al. Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells. J Med Virol. 2008;80(1):134–46.
29. Munoz-Jordan JL, Sanchez-Burgos GG, Laurent-Rolle M, Garcia-Sastre A. Inhibition of interferon signaling by dengue virus. Proc Natl Acad Sci U S A. 2003;100(24):14333–8.
30. D'Agostino DM, Bernardi P, Chieco-Bianchi L, Ciminale V. Mitochondria as functional targets of proteins coded by human tumor viruses. Adv Cancer Res. 2005;94:87–142.
31. Aguirre S, Maestre AM, Pagni S, Patel JR, Savage T, Gutman D, Maringer K, Bernal-Rubio D, Shabman RS, Simon V, Rodriguez-Madoz JR, Mulder LC, Barber GN, Fernandez-Sesma A. DENV inhibits type I IFN production in infected cells by cleaving human STING. PLoS Pathog. 2012;8(10):e1002934. PMCID: 3464218. This paper identified human STING as a target of the DENV NS2B3 protease complex and showed that cleavage of STING by NS2B3 was involved in inhibition of IFN induction.
32. Rothman AL. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol. 2011;11(8):532–43.
33. Nimmerjahn F, Milosevic S, Behrends U, Jaffee EM, Pardoll DM, Bornkamm GW, et al. Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. Eur J Immunol. 2003;33(5):1250–9.
34. Dengjel J, Schoor O, Fischer R, Reich M, Kraus M, Muller M, et al. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proc Natl Acad Sci U S A. 2005;102(22):7922–7. PMCID: 1142372.
35. Schmid D, Pypaert M, Munz C. Antigen-loading compartments for major histocompatibility complex class II molecules continuously receive input from autophagosomes. Immunity. 2007;26(1):79–92. PMCID: 1805710.
36. Li Y, Wang LX, Yang G, Hao F, Urba WJ, Hu HM. Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res. 2008;68(17):6889–95. PMCID: 2905686.
37. Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, Chairunsri A, et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med. 2003;9(7):921–7.
38. Friberg H, Bashyam H, Toyosaki-Maeda T, Potts JA, Greenough T, Kalayanarooj S, Gibbons RV, Nisalak A, Srikiatkhachorn A, Green S, Stephens HA, Rothman AL, Mathew A. Cross-reactivity and expansion of dengue-specific T cells during acute primary and secondary infections in humans. Sci Rep. 2011;1:51. PMCID: 3216538. The study involved a comprehensive analysis of tetramer-specific T cells in blood samples collected during acute primary and secondary DENV infections. Data from this study challenge previous models of T cell expansion kinetics, activation, and serotype-cross-reactivity.
39. Duangchinda T, Dejnirattisai W, Vasanawathana S, Limpitikul W, Tangthawornchaikul N, Malasit P, et al. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci U S A. 2010;107(39):16922–7. This study involved the assessment of DENV-specific T cell responses in primary and secondary infection with respect to disease outcome. The data demonstrate that T cell functional profiles differ in mild versus severe disease.
40. Dong T, Moran E, Vinh Chau N, Simmons C, Luhn K, Peng Y, et al. High pro-inflammatory cytokine secretion and loss of high avidity cross-reactive cytotoxic T-cells during the course of secondary dengue virus infection. PLoS ONE. 2007;2(12):e1192.
41. Mangada MM, Endy TP, Nisalak A, Chunsuttiwat S, Vaughn DW, Libraty DH, et al. Dengue-specific T cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus infections in Thai schoolchildren. J Infect Dis. 2002;185(12):1697–703.
42. Mongkolsapaya J, Duangchinda T, Dejnirattisai W, Vasanawathana S, Avirutnan P, Jairungsri A, et al. T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal? J Immunol. 2006;176(6):3821–9.
43. Zivna I, Green S, Vaughn DW, Kalayanarooj S, Stephens HAF, Chandanayingyong D, et al. T cell responses to an HLA B*07-restricted epitope on the dengue NS3 protein correlate with disease severity. J Immunol. 2002;168:5959–65.
44. Townsley E, Woda M, Thomas SJ, Kalayanarooj S, Gibbons RV, Nisalak A, Srikiatkhachorn A, Green S, Stephens HA, Rothman AL, Mathew A. Distinct activation phenotype of a highly conserved novel HLA-B57-restricted epitope during dengue virus infection. Immunology. 2013. This study identified a highly conserved epitope on the DENV NS1 protein. Flow cytometry analyses demonstrated that CD71 was a novel marker of T cell activation specific for tetramer-positive T cells.
45. Dung NT, Duyen HT, Thuy NT, Ngoc TV, Chau NV, Hien TT, et al. Timing of CD8+ T cell responses in relation to commencement of capillary leakage in children with dengue. J Immunol. 2010;184(12):7281–7.
46. Stephens HA. HLA and other gene associations with dengue disease severity. Curr Top Microbiol Immunol. 2010;338:99–114.
47. Friberg H, Burns L, Woda M, Kalayanarooj S, Endy TP, Stephens HA, et al. Memory CD8+ T cells from naturally acquired primary dengue virus infection are highly cross-reactive. Immunol Cell Biol. 2011;89(1):122–9. PMCID: 2929403.
48. Beaumier CM, Mathew A, Bashyam HS, Rothman AL. Cross-reactive memory CD8(+) T cells alter the immune response to heterologous secondary dengue virus infections in mice in a sequence-specific manner. J Infect Dis. 2008;197(4):608–17.
49. Beaumier CM, Rothman AL. Cross-reactive memory CD4+ T cells alter the CD8+ T-cell response to heterologous secondary dengue virus infections in mice in a sequence-specific manner. Viral Immunol. 2009;22(3):215–9.
50. Beaumier CM, Jaiswal S, West KY, Friberg H, Mathew A, Rothman AL. Differential in vivo clearance and response to secondary heterologous infections by H2(b)-restricted dengue virus-specific CD8+ T cells. Viral Immunol. 2010;23(5):477–85.
51. Weiskopf D, Yauch LE, Angelo MA, John DV, Greenbaum JA, Sidney J, et al. Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design. J Immunol. 2011;187(8):4268–79. PMCID: 3186824.
52. Jaiswal S, Pearson T, Friberg H, Shultz LD, Greiner DL, Rothman AL, et al. Dengue virus infection and virus-specific HLA-A2 restricted immune responses in humanized NOD-scid IL2rgammanull mice. PLoS ONE. 2009;4(10):e7251.
53. Jaiswal S, Pazoles P, Woda M, Shultz LD, Greiner DL, Brehm MA, et al. Enhanced humoral and HLA-A2-restricted dengue virus-specific T-cell responses in humanized BLT NSG mice. Immunology. 2012;136(3):334–43. PMCID: 3385033.
54. Thomas SJ, Hombach J, Barrett A. Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development. Vaccine. 2009;27(3):355–68.
55. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol. 2009;10(1):116–25.
56. Endy TP, Chunsuttiwat S, Nisalak A, Libraty DH, Green S, Rothman AL, et al. Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in kamphaeng phet, Thailand. Am J Epidemiol. 2002;156(1):40–51.
57. Yoon IK, Rothman AL, Tannitisupawong D, Srikiatkhachorn A, Jarman RG, Aldstadt J, et al. Underrecognized mildly symptomatic viremic dengue virus infections in rural Thai schools and villages. J Infect Dis. 2012;206(3):389–98. PMCID: 3490697.
58. Hatch S, Endy TP, Thomas S, Mathew A, Potts J, Pazoles P, et al. Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection. J Infect Dis. 2011;203:1282–91. This study measured the frequencies of DENV-specific memory T cells in PBMC collected prior to secondary DENV infections. The data showed significantly higher IFN γ-producing T cell frequencies in subjects who had subclinical secondary infections.
59. Mangada MM, Rothman AL. Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes. J Immunol. 2005;175(4):2676–83.
60. Stephens HA, Klaythong R, Sirikong M, Vaughn DW, Green S, Kalayanarooj S, et al. HLA-A and -B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais. Tissue Antigens. 2002;60(4):309–18.
61. Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA, Fernando AN, Broadwater A, Kolla RV, De Silva AD, de Silva AM, Mattia KA, Doranz BJ, Grey HM, Shresta S, Peters B, Sette A. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A. 2013;110(22):E2046–53. PMCID: 3670335. This study tested for IFNγ ELISPOT responses to an extensive panel of DENV peptides in PBMC from healthy adults from Sri Lanka. The data show significantly higher frequencies of T cells that are restricted by HLA alleles that have shown associations with resistance to severe dengue illness.
62. Rothman AL, Kanesa-thasan N, West K, Janus J, Saluzzo J, Ennis FA. Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine. Vaccine. 2001;19(32):4694–9.
63. Gwinn W, Sun W, Innis BL, Caudill J, King AD. Serotype-specific T(H)1 responses in recipients of two doses of candidate live-attenuated dengue virus vaccines. Am J Trop Med Hyg. 2003;69(6 Suppl):39–47.
64. Guy B, Nougarede N, Begue S, Sanchez V, Souag N, Carre M, et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine. 2008;26(45):5712–21.
65. Lindow JC, Durbin AP, Whitehead SS, Pierce KK, Carmolli MP, Kirkpatrick BD. Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles. Vaccine. 2013;31(33):3347–52. PMCID: 3777849.
66. Harenberg A, Begue S, Mamessier A, Gimenez-Fourage S, Ching Seah C, Wei Liang A, et al. Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore. Hum Vaccin Immunother. 2013;9(11).
67. Thakur A, Pedersen LE, Jungersen G. Immune markers and correlates of protection for vaccine induced immune responses. Vaccine. 2012;30(33):4907–20.
68. Tan AC, Eriksson EM, Kedzierska K, Deliyannis G, Valkenburg SA, Zeng W, et al. Polyfunctional CD8(+) T cells are associated with the vaccination-induced control of a novel recombinant influenza virus expressing an HCV epitope. Antiviral Res. 2012;94(2):168–78.
69. Betts MR, Harari A. Phenotype and function of protective T cell immune responses in HIV. Curr Opin HIV AIDS. 2008;3(3):349–55.
70. Gunther VJ, Putnak R, Eckels KH, Mammen MP, Scherer JM, Lyons A, et al. A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness. Vaccine. 2011;29(22):3895–904. This study measured DENV-specific cytokine responses in 10 subjects who had received a tetravalent DENV vaccine and were then experimentally challenged with DENV-1 or DENV-3. Subjects who had protective immunity against the experimental challenge were characterized by the sustained ability to produce IFNγ during the 14-day period after challenge.
71. Thomas SJ, Endy TP. Vaccines for the prevention of dengue: development update. Human Vaccines. 2011;7(6):674–84.
72. Polack FP. Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple. Pediatr Res. 2007;62(1):111–5.